StreetInsider.com News Articles

Mesoblast Limited (MSB:AU) (MESO) PT Lowered to AUD3.52 at Canaccord

Mon, 19 Oct 2026 09:05:02 -0400

Canaccord analyst Madeleine Williams lowered the price target on Mesoblast Limited (MSB:AU) (NASDAQ: MESO) to AUD3.52 (from AUD3.56) while maintaining a Buy rating.

Mesoblast Limited (MSB:AU) (MESO) PT Lowered to AUD3.52 at Canaccord

Mon, 19 Oct 2026 09:05:02 -0400

Canaccord analyst Madeleine Williams lowered the price target on Mesoblast Limited (MSB:AU) (NASDAQ: MESO) to AUD3.52 (from AUD3.56) while maintaining a Buy rating.

Mesoblast Limited (MSB:AU) (MESO) PT Lowered to AUD3.52 at Canaccord

Mon, 19 Oct 2026 09:05:02 -0400

Canaccord analyst Madeleine Williams lowered the price target on Mesoblast Limited (MSB:AU) (NASDAQ: MESO) to AUD3.52 (from AUD3.56) while maintaining a Buy rating.

Mesoblast Limited (MSB:AU) (MESO) PT Lowered to AUD3.52 at Canaccord

Mon, 19 Oct 2026 09:05:02 -0400

Canaccord analyst Madeleine Williams lowered the price target on Mesoblast Limited (MSB:AU) (NASDAQ: MESO) to AUD3.52 (from AUD3.56) while maintaining a Buy rating.

Form 6-K MESOBLAST LTD For: Oct 16

Fri, 16 Oct 2026 06:03:00 -0400

si-local-file:///var/storage/secattach/20261016/27195243.html

Form 6-K MESOBLAST LTD For: Oct 14

Thu, 15 Oct 2026 07:38:00 -0400

si-local-file:///var/storage/secattach/20261015/27189723.html

Form 6-K MESOBLAST LTD For: Oct 13

Tue, 13 Oct 2026 06:28:00 -0400

si-local-file:///var/storage/secattach/20261013/27176552.html

Mesoblast Limited (MESO) Reiterated at Overweight by Cantor Fitzgerald

Thu, 24 Sep 2026 07:10:27 -0400

Cantor Fitzgerald analyst Olivia Brayer Saunders reiterated an Overweight rating on Mesoblast Limited (NASDAQ: MESO).

The analyst commented, "We've been getting more questions on MESO lately - and the conversation is shifting to valuation and what can drive the next leg from here. Ryoncil has had a strong launch in pediatric SR-aGVHD, but at this point, we think the stock is already pricing in some value for Ryoncil's success beyond pediatrics. That's why the adult phase 3 matters so much from here. The adult opportunity is ~3x larger than pediatrics, according to management, and MESO has been transparent that they see

FDA approves new potency assay for Mesoblast's Ryoncil product

Thu, 24 Sep 2026 07:00:14 -0400

Mesoblast Limited (Nasdaq: MESO; ASX: MSB) announced that the U.S. Food and Drug Administration has approved a new potency assay, called the T-cell Proliferation Inhibition BioAssay (TIBA), for use in releasing and monitoring commercial lots of its mesenchymal stromal cell product Ryoncil (remestemcel-L-rknd).

The TIBA assay is designed to detect shifts in potency that could occur during manufacturing process changes or production at new facilities. It will be used alongside two existing potency assays — one measuring IL-2Rα inhibition and another measuring Cell Adhesion and Proliferation — as part of a matrix to release each commercial batch of Ryoncil under the

Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product

Thu, 24 Sep 2026 07:00:00 -0400

NEW YORK, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has received approval from the United States Food and Drug Administration (FDA) to implement a new potency assay, T-cell Proliferation Inhibition BioAssay (TIBA), for release and stability monitoring of all new commercial product lots of its FDA-approved mesenchymal stromal cell (MSC) product Ryoncil^® (remestemcel-L-rknd).

The TIBA assay will ensure sufficient sensitivity to detect any shifts in potency of the commercial product that could arise during changes in manufacturing processes or

Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product

Thu, 24 Sep 2026 07:00:00 -0400

The TIBA assay will ensure sufficient sensitivity to detect any shifts in potency of the commercial product that could arise during changes in manufacturing processes or

Form 6-K MESOBLAST LTD For: Sep 24

Thu, 24 Sep 2026 06:01:00 -0400

si-local-file:///var/storage/secattach/20260924/27098389.html

Piper Sandler on Biotechnology: 'Look for Biotech to Outperform through YE:26'